Combined chemotherapy (platinum doublet with third-generation molecules Gemcitabine/Vinorelbine or taxanes) is the first-line therapy in patients with metastatic NSCLC, without driver mutations, regardless of PD-L1 expression, having contraindications to immunotherapy and offers a 1-year survival of 40%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.